These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 36435945)

  • 1. Intratracheal trimerized nanobody cocktail administration suppresses weight loss and prolongs survival of SARS-CoV-2 infected mice.
    Nagata K; Utsumi D; Asaka MN; Maeda R; Shirakawa K; Kazuma Y; Nomura R; Horisawa Y; Yanagida Y; Kawai Y; Sato K; Yamaoka Y; Miyakawa K; Ryo A; Yasutomi Y; Imura A; Takaori-Kondo A
    Commun Med (Lond); 2022 Nov; 2(1):152. PubMed ID: 36435945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
    Aksu M; Kumar P; Güttler T; Taxer W; Gregor K; Mußil B; Rymarenko O; Stegmann KM; Dickmanns A; Gerber S; Reineking W; Schulz C; Henneck T; Mohamed A; Pohlmann G; Ramazanoglu M; Mese K; Groß U; Ben-Yedidia T; Ovadia O; Fischer DW; Kamensky M; Reichman A; Baumgärtner W; von Köckritz-Blickwede M; Dobbelstein M; Görlich D
    Antiviral Res; 2024 Jan; 221():105778. PubMed ID: 38065245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1.
    Wang J; Shi B; Chen H; Yu M; Wang P; Qian Z; Hu K; Wang J
    Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
    Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
    Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration.
    Ma H; Zhang X; Zeng W; Zhou J; Chi X; Chen S; Zheng P; Wang M; Wu Y; Zhao D; Gong F; Lin H; Sun H; Yu C; Shi Z; Hu X; Zhang H; Jin T; Chiu S
    Cell Discov; 2022 Dec; 8(1):132. PubMed ID: 36494344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains.
    Yao H; Wang H; Zhang Z; Lu Y; Zhang Z; Zhang Y; Xiong X; Wang Y; Wang Z; Yang H; Zhao J; Xu W
    MedComm (2020); 2023 Dec; 4(6):e397. PubMed ID: 37901798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2.
    Nikitin PA; DiMuzio JM; Dowling JP; Patel NB; Bingaman-Steele JL; Heimbach BC; Henriquez N; Nicolescu C; Polley A; Sikorski EL; Howanski RJ; Nath M; Shukla H; Scheaffer SM; Finn JP; Liang LF; Smith T; Storm N; McKay LGA; Johnson RI; Malsick LE; Honko AN; Griffiths A; Diamond MS; Sarma P; Geising DH; Morin MJ; Robinson MK
    Sci Immunol; 2022 Sep; 7(75):eabl9943. PubMed ID: 35771946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
    Verkhivker G
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.
    Zhang L; Narayanan KK; Cooper L; Chan KK; Devlin CA; Aguhob A; Shirley K; Rong L; Rehman J; Malik AB; Procko E
    bioRxiv; 2022 Mar; ():. PubMed ID: 35378764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
    Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
    Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
    Lu J; Yin Q; Pei R; Zhang Q; Qu Y; Pan Y; Sun L; Gao D; Liang C; Yang J; Wu W; Li J; Cui Z; Wang Z; Li X; Li D; Wang S; Duan K; Guan W; Liang M; Yang X
    Virol Sin; 2022 Apr; 37(2):238-247. PubMed ID: 35527227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
    Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
    Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants.
    Pavan MF; Bok M; Juan RBS; Malito JP; Marcoppido GA; Franco DR; Militello DA; Schammas JM; Bari S; ; Stone WB; López K; Porier DL; Muller J; Auguste AJ; Yuan L; Wigdorovitz A; Parreño V; Ibañez LI
    bioRxiv; 2023 Mar; ():. PubMed ID: 36993215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A fourth dose of Omicron RBD vaccine enhances broad neutralization against SARS-CoV-2 variants including BA.1 and BA.2 in vaccinated mice.
    Zhou B; Song S; Guo H; Zhou X; Fan Q; Liu W; Cheng L; Ge X; Ju B; Zhang Z
    J Med Virol; 2022 Aug; 94(8):3992-3997. PubMed ID: 35474319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1 and BA.2 have higher stability.
    Hirose R; Itoh Y; Ikegaya H; Miyazaki H; Watanabe N; Yoshida T; Bandou R; Daidoji T; Nakaya T
    Clin Microbiol Infect; 2022 Nov; 28(11):1486-1491. PubMed ID: 35640841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
    Maeda R; Fujita J; Konishi Y; Kazuma Y; Yamazaki H; Anzai I; Watanabe T; Yamaguchi K; Kasai K; Nagata K; Yamaoka Y; Miyakawa K; Ryo A; Shirakawa K; Sato K; Makino F; Matsuura Y; Inoue T; Imura A; Namba K; Takaori-Kondo A
    Commun Biol; 2022 Jul; 5(1):669. PubMed ID: 35794202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern.
    García-Vega M; Melgoza-González EA; Hernández-Valenzuela S; Hinojosa-Trujillo D; Reséndiz-Sandoval M; Llamas-Covarrubias MA; Loza-López M; Valenzuela O; Soto-Gaxiola A; Hernández-Oñate MA; Mata-Haro V; Cassaniti I; Sammartino JC; Ferrari A; Simonelli L; Pedotti M; Sun R; Zuo F; Baldanti F; Varani L; Marcotte H; Pan-Hammarström Q; Hernández J
    iScience; 2023 Apr; 26(4):106562. PubMed ID: 37063467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.
    Fenwick C; Turelli P; Ni D; Perez L; Lau K; Herate C; Marlin R; Lana E; Pellaton C; Raclot C; Esteves-Leuenberger L; Campos J; Farina A; Fiscalini F; Dereuddre-Bosquet N; Relouzat F; Abdelnabi R; Foo CS; Neyts J; Leyssen P; Lévy Y; Pojer F; Stahlberg H; LeGrand R; Trono D; Pantaleo G
    Nat Microbiol; 2022 Sep; 7(9):1376-1389. PubMed ID: 35879526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.